M L Loh

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi request reprint TEL/AML1-positive pediatric leukemia: prognostic significance and therapeutic approaches
    Mignon L Loh
    Department of Pediatric Hematology Oncology, University of California San Francisco, San Francisco, California 94143 0519, USA
    Curr Opin Hematol 9:345-52. 2002
  2. doi request reprint Childhood myelodysplastic syndrome: focus on the approach to diagnosis and treatment of juvenile myelomonocytic leukemia
    Mignon L Loh
    Department of Pediatrics and the Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94143, USA
    Hematology Am Soc Hematol Educ Program 2010:357-62. 2010
  3. ncbi request reprint PTPN11 mutations in pediatric patients with acute myeloid leukemia: results from the Children's Cancer Group
    M L Loh
    Department of Pediatrics, University of California, San Francisco, CA 94143, USA
    Leukemia 18:1831-4. 2004
  4. ncbi request reprint Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis
    Mignon L Loh
    Department of Pediatrics, University of California, Rm HSE 302 Box 0519, San Francisco, CA 94143, USA
    Blood 103:2325-31. 2004
  5. ncbi request reprint Treatment of infantile fibrosarcoma with chemotherapy and surgery: results from the Dana-Farber Cancer Institute and Children's Hospital, Boston
    Mignon L Loh
    Department of Pediatric Hematology Oncology, University of California San Francisco, San Francisco, CA 94143 0519, USA
    J Pediatr Hematol Oncol 24:722-6. 2002
  6. pmc Mutations in CBL occur frequently in juvenile myelomonocytic leukemia
    Mignon L Loh
    Department of Pediatrics and the Comprehensive Cancer Center, University of California, San Francisco, California, USA
    Blood 114:1859-63. 2009
  7. pmc Prospective analysis of TEL/AML1-positive patients treated on Dana-Farber Cancer Institute Consortium Protocol 95-01
    Mignon L Loh
    Department of Pediatrics, Comprehensive Cancer Center, University of California, San Francisco, CA 94143, USA
    Blood 107:4508-13. 2006
  8. pmc The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative disease
    Christian P Kratz
    University of California, Room HSE 302 Box 0519, San Francisco, CA 94143, USA
    Blood 106:2183-5. 2005
  9. pmc Functional analysis of leukemia-associated PTPN11 mutations in primary hematopoietic cells
    Suzanne Schubbert
    Department of Pediatrics, University of California at San Francisco, 513 Parnassus Ave, HSE 302, San Francisco, CA 94143, USA
    Blood 106:311-7. 2005
  10. ncbi request reprint Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia
    Mohamed Bentires-Alj
    Cancer Biology Program, Department of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    Cancer Res 64:8816-20. 2004

Collaborators

Detail Information

Publications21

  1. ncbi request reprint TEL/AML1-positive pediatric leukemia: prognostic significance and therapeutic approaches
    Mignon L Loh
    Department of Pediatric Hematology Oncology, University of California San Francisco, San Francisco, California 94143 0519, USA
    Curr Opin Hematol 9:345-52. 2002
    ..Incorporating knowledge of this gene rearrangement into treatment decisions serves as a paradigm for translating molecular discoveries into clinically meaningful data to direct patient care and improve outcome...
  2. doi request reprint Childhood myelodysplastic syndrome: focus on the approach to diagnosis and treatment of juvenile myelomonocytic leukemia
    Mignon L Loh
    Department of Pediatrics and the Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94143, USA
    Hematology Am Soc Hematol Educ Program 2010:357-62. 2010
    ..This review is focused on the genetic abnormalities that occur in JMML, with particular attention to germ-line predisposition syndromes associated with the disorder. Current approaches to therapy are also discussed...
  3. ncbi request reprint PTPN11 mutations in pediatric patients with acute myeloid leukemia: results from the Children's Cancer Group
    M L Loh
    Department of Pediatrics, University of California, San Francisco, CA 94143, USA
    Leukemia 18:1831-4. 2004
    ..There was no difference in clinical outcome for patients with and without PTPN11 mutations. These characteristics identify a subset of pediatric AML with PTPN11 mutations that share clinical and biologic features with JMML...
  4. ncbi request reprint Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis
    Mignon L Loh
    Department of Pediatrics, University of California, Rm HSE 302 Box 0519, San Francisco, CA 94143, USA
    Blood 103:2325-31. 2004
    ..We conclude that SHP-2 is an important cellular PTPase that is mutated in myeloid malignancies. Further investigation is required to clarify how these mutant proteins interact with Ras and other effectors to deregulate myeloid growth...
  5. ncbi request reprint Treatment of infantile fibrosarcoma with chemotherapy and surgery: results from the Dana-Farber Cancer Institute and Children's Hospital, Boston
    Mignon L Loh
    Department of Pediatric Hematology Oncology, University of California San Francisco, San Francisco, CA 94143 0519, USA
    J Pediatr Hematol Oncol 24:722-6. 2002
    ..To retrospectively evaluate the treatment and outcome of patients diagnosed with infantile fibrosarcoma at the Dana-Farber Cancer Institute and Children's Hospital, Boston...
  6. pmc Mutations in CBL occur frequently in juvenile myelomonocytic leukemia
    Mignon L Loh
    Department of Pediatrics and the Comprehensive Cancer Center, University of California, San Francisco, California, USA
    Blood 114:1859-63. 2009
    ..Moreover, the exclusivity of CBL mutations with respect to other Ras pathway-associated mutations indicates that CBL may have a role in deregulating this key pathway in JMML...
  7. pmc Prospective analysis of TEL/AML1-positive patients treated on Dana-Farber Cancer Institute Consortium Protocol 95-01
    Mignon L Loh
    Department of Pediatrics, Comprehensive Cancer Center, University of California, San Francisco, CA 94143, USA
    Blood 107:4508-13. 2006
    ..However, factors such as age at diagnosis and presenting leukocyte count should be taken into consideration when treating this group of patients...
  8. pmc The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative disease
    Christian P Kratz
    University of California, Room HSE 302 Box 0519, San Francisco, CA 94143, USA
    Blood 106:2183-5. 2005
    ..This supports the need to characterize the spectrum of hematologic abnormalities in individuals with NS and to better define the impact of the PTPN11 lesion on the disease course in patients with NS/MPD and JMML...
  9. pmc Functional analysis of leukemia-associated PTPN11 mutations in primary hematopoietic cells
    Suzanne Schubbert
    Department of Pediatrics, University of California at San Francisco, 513 Parnassus Ave, HSE 302, San Francisco, CA 94143, USA
    Blood 106:311-7. 2005
    ..Mutant SHP-2 proteins induce aberrant growth in multiple hematopoietic compartments, which supports a primary role of hyperactive Ras in the pathogenesis of JMML...
  10. ncbi request reprint Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia
    Mohamed Bentires-Alj
    Cancer Biology Program, Department of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    Cancer Res 64:8816-20. 2004
    ..Our data demonstrate that mutations in PTPN11 occur at low frequency in several human cancers, especially neuroblastoma and AML, and suggest that Shp2 may be a novel target for antineoplastic therapy...
  11. ncbi request reprint Acquired PTPN11 mutations occur rarely in adult patients with myelodysplastic syndromes and chronic myelomonocytic leukemia
    Mignon L Loh
    Department of Pediatrics, University of California, San Francisco, CA, USA
    Leuk Res 29:459-62. 2005
    ..Here, we investigated contribution of PTPN11 mutations to adult MDS and CMML pathogenesis. Our results indicate that PTPN11 lesions might play a role in adult MDS/CMML pathogenesis but do not represent a major molecular event...
  12. ncbi request reprint SHP-2 and myeloid malignancies
    Marco Tartaglia
    Dipartimento di Biologia Cellulare e Neuroscienze, Istituto Superiore di Sanita, Rome, Italy
    Curr Opin Hematol 11:44-50. 2004
    ..Specifically, we discuss the role of inherited and somatic mutations that result in SHP-2 gain-of-function in human disease, including myeloid malignancies...
  13. ncbi request reprint Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols
    Elly Barry
    Department of Pediatric Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 25:813-9. 2007
    ..We report the outcome of adolescents treated on Dana-Farber Cancer Institute (DFCI; Boston, MA) ALL Consortium Protocols conducted between 1991 and 2000...
  14. ncbi request reprint Inherited predispositions and hyperactive Ras in myeloid leukemogenesis
    Jennifer O Lauchle
    Department of Pediatrics and Comprehensive Cancer Center, University of California, San Francisco, California 94143, USA
    Pediatr Blood Cancer 46:579-85. 2006
    ..These strains model human disease features and provide an opportunity to investigate novel therapeutic strategies that may ultimately cure JMML and other myeloid malignancies characterized by hyperactive Ras...
  15. ncbi request reprint Cytogenetics of Hispanic and White children with acute lymphoblastic leukemia in California
    Melinda C Aldrich
    University of California Berkeley, 2150 Shattuck Avenue, Suite 500, Berkeley, CA 94720 7380, USA
    Cancer Epidemiol Biomarkers Prev 15:578-81. 2006
    ..The mechanistic basis for this 2-fold variation in frequency of TEL-AML1 may be due to ethnic-specific risk factors or genetics and should be explored further...
  16. pmc Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG)
    Kirk R Schultz
    Children s Oncology Group, Department of Pediatrics, BC Children s Hospital, University of British Columbia, Vancouver, Canada
    Blood 109:926-35. 2007
    ....
  17. pmc The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia
    Ross L Levine
    Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Blood 106:3377-9. 2005
    ..These data indicate that the JAK2V617F allele is present in acute and chronic myeloid malignancies but not in lymphoid malignancies...
  18. pmc Single-cell profiling identifies aberrant STAT5 activation in myeloid malignancies with specific clinical and biologic correlates
    Nikesh Kotecha
    Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA 94305, USA
    Cancer Cell 14:335-43. 2008
    ..This signature was a specific feature involving JAK-STAT signaling, suggesting a critical role of this pathway in the biological mechanism of this disorder and indicating potential targets for future therapies...
  19. ncbi request reprint Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia
    Adolfo A Ferrando
    Department of Pediatric Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02142, USA
    Cancer Cell 1:75-87. 2002
    ..Our results illustrate the power of gene expression profiles to elucidate transformation pathways relevant to human leukemia...
  20. ncbi request reprint Congenital leukemia cutis with subsequent development of leukemia
    Inga Hofmann Zhang
    Department of Pediatrics, University of California San Francisco, California 94143 0519, USA
    J Am Acad Dermatol 54:S22-7. 2006
    ..The patient died of refractory leukemia and secondary fungal disease. This case report supports the observation that leukemia cutis with an 11q23 rearrangement should be treated aggressively...
  21. ncbi request reprint Prenatal origin of TEL-AML1-positive acute lymphoblastic leukemia in children born in California
    Cliona M McHale
    School of Public Health, University of California, Berkeley 94720 7360, USA
    Genes Chromosomes Cancer 37:36-43. 2003
    ..Secondary changes were also similar to those described previously, with deletion of the second TEL allele being the most common. Other secondary changes included duplication of the fusion gene, trisomy 21, and monosomy X...